-
Je něco špatně v tomto záznamu ?
Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer
SM. Advani, PS. Advani, DW. Brown, SM. DeSantis, K. Korphaisarn, HM. VonVille, J. Bressler, DS. Lopez, JS. Davis, CR. Daniel, AM. Sarshekeh, D. Braithwaite, MD. Swartz, S. Kopetz,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, metaanalýza, systematický přehled
NLK
BioMedCentral
od 2001-12-01
BioMedCentral Open Access
od 2001
Directory of Open Access Journals
od 2001
Free Medical Journals
od 2001
PubMed Central
od 2001
Europe PubMed Central
od 2001
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2001-01-01
Open Access Digital Library
od 2001-01-01
Open Access Digital Library
od 2001-01-01
Medline Complete (EBSCOhost)
od 2001-01-01
Health & Medicine (ProQuest)
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2001
Springer Nature OA/Free Journals
od 2001-12-01
- MeSH
- CpG ostrůvky genetika MeSH
- fenotyp * MeSH
- genetická heterogenita MeSH
- kohortové studie MeSH
- kolorektální nádory genetika MeSH
- lidé MeSH
- metylace DNA genetika MeSH
- pití alkoholu škodlivé účinky genetika MeSH
- prevalence MeSH
- promotorové oblasti (genetika) genetika MeSH
- publikační zkreslení MeSH
- rizikové faktory MeSH
- umlčování genů MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
- systematický přehled MeSH
- Geografické názvy
- Česká republika MeSH
- Indie MeSH
BACKGROUND: CpG Island Methylator Phenotype (CIMP) is an epigenetic phenotype in CRC characterized by hypermethylation of CpG islands in promoter regions of tumor suppressor genes, leading to their transcriptional silencing and loss of function. While the prevalence of CRC differs across geographical regions, no studies have compared prevalence of CIMP-High phenotype across regions. The purpose of this project was to compare the prevalence of CIMP across geographical regions after adjusting for variations in methodologies to measure CIMP in a meta-analysis. METHODS: We searched PubMed, Medline, and Embase for articles focusing on CIMP published from 2000 to 2018. Two reviewers independently identified 111 articles to be included in final meta-analysis. We classified methods used to quantify CIMP into 4 categories: a) Classical (MINT marker) Panel group b) Weisenberg-Ogino (W-O) group c) Human Methylation Arrays group and d) Miscellaneous group. We compared the prevalence of CIMP across geographical regions after correcting for methodological variations using meta-regression techniques. RESULTS: The pooled prevalence of CIMP-High across all studies was 22% (95% confidence interval:21-24%; I2 = 94.75%). Pooled prevalence of CIMP-H across Asia, Australia, Europe, North America and South America was 22, 21, 21, 27 and 25%, respectively. Meta-regression analysis identified no significant differences in the prevalence of CIMP-H across geographical regions after correction for methodological variations. In exploratory analysis, we observed variations in CIMP-H prevalence across countries. CONCLUSION: Although no differences were found for CIMP-H prevalence across countries, further studies are needed to compare the influence of demographic, lifestyle and environmental factors in relation to the prevalence of CIMP across geographical regions.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20015865
- 003
- CZ-PrNML
- 005
- 20201119104845.0
- 007
- ta
- 008
- 201012s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12885-019-6144-9 $2 doi
- 035 __
- $a (PubMed)31623592
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Advani, Shailesh Mahesh $u Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0426, Houston, TX, 77030, USA. Shailesh.advani@nih.gov. Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, 20007, USA. Shailesh.advani@nih.gov. Social Behavioral Research Branch, National Human Genome Research Institute, National Institute of Health, Bethesda, MD, 20892, USA. Shailesh.advani@nih.gov.
- 245 10
- $a Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer / $c SM. Advani, PS. Advani, DW. Brown, SM. DeSantis, K. Korphaisarn, HM. VonVille, J. Bressler, DS. Lopez, JS. Davis, CR. Daniel, AM. Sarshekeh, D. Braithwaite, MD. Swartz, S. Kopetz,
- 520 9_
- $a BACKGROUND: CpG Island Methylator Phenotype (CIMP) is an epigenetic phenotype in CRC characterized by hypermethylation of CpG islands in promoter regions of tumor suppressor genes, leading to their transcriptional silencing and loss of function. While the prevalence of CRC differs across geographical regions, no studies have compared prevalence of CIMP-High phenotype across regions. The purpose of this project was to compare the prevalence of CIMP across geographical regions after adjusting for variations in methodologies to measure CIMP in a meta-analysis. METHODS: We searched PubMed, Medline, and Embase for articles focusing on CIMP published from 2000 to 2018. Two reviewers independently identified 111 articles to be included in final meta-analysis. We classified methods used to quantify CIMP into 4 categories: a) Classical (MINT marker) Panel group b) Weisenberg-Ogino (W-O) group c) Human Methylation Arrays group and d) Miscellaneous group. We compared the prevalence of CIMP across geographical regions after correcting for methodological variations using meta-regression techniques. RESULTS: The pooled prevalence of CIMP-High across all studies was 22% (95% confidence interval:21-24%; I2 = 94.75%). Pooled prevalence of CIMP-H across Asia, Australia, Europe, North America and South America was 22, 21, 21, 27 and 25%, respectively. Meta-regression analysis identified no significant differences in the prevalence of CIMP-H across geographical regions after correction for methodological variations. In exploratory analysis, we observed variations in CIMP-H prevalence across countries. CONCLUSION: Although no differences were found for CIMP-H prevalence across countries, further studies are needed to compare the influence of demographic, lifestyle and environmental factors in relation to the prevalence of CIMP across geographical regions.
- 650 _2
- $a pití alkoholu $x škodlivé účinky $x genetika $7 D000428
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a kolorektální nádory $x genetika $7 D015179
- 650 _2
- $a CpG ostrůvky $x genetika $7 D018899
- 650 _2
- $a metylace DNA $x genetika $7 D019175
- 650 _2
- $a umlčování genů $7 D020868
- 650 _2
- $a genetická heterogenita $7 D018740
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a fenotyp $7 D010641
- 650 _2
- $a prevalence $7 D015995
- 650 _2
- $a promotorové oblasti (genetika) $x genetika $7 D011401
- 650 _2
- $a publikační zkreslení $7 D017594
- 650 _2
- $a rizikové faktory $7 D012307
- 651 _2
- $a Česká republika $7 D018153
- 651 _2
- $a Indie $7 D007194
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a metaanalýza $7 D017418
- 655 _2
- $a systematický přehled $7 D000078182
- 700 1_
- $a Advani, Pragati Shailesh $u Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Institutes of Health, National Cancer Institute, Rockville, MD, 20850, USA.
- 700 1_
- $a Brown, Derek W $u Department of Biostatistics and Data Science, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
- 700 1_
- $a DeSantis, Stacia M $u Department of Biostatistics and Data Science, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
- 700 1_
- $a Korphaisarn, Krittiya $u Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0426, Houston, TX, 77030, USA.
- 700 1_
- $a VonVille, Helena M $u Library, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
- 700 1_
- $a Bressler, Jan $u Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
- 700 1_
- $a Lopez, David S $u Division of Urology- UTHealth McGovern Medical School, Houston, TX, 77030, USA. Department of Preventive Medicine and Community Health, UTMB Health-School of Medicine, Galveston, TX, 77555-1153, USA.
- 700 1_
- $a Davis, Jennifer S $u Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
- 700 1_
- $a Daniel, Carrie R $u Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
- 700 1_
- $a Sarshekeh, Amir Mehrvarz $u Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0426, Houston, TX, 77030, USA.
- 700 1_
- $a Braithwaite, Dejana $u Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, 20007, USA.
- 700 1_
- $a Swartz, Michael D $u Department of Biostatistics and Data Science, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
- 700 1_
- $a Kopetz, Scott $u Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0426, Houston, TX, 77030, USA. skopetz@mdanderson.org.
- 773 0_
- $w MED00008171 $t BMC cancer $x 1471-2407 $g Roč. 19, č. 1 (2019), s. 964
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31623592 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201012 $b ABA008
- 991 __
- $a 20201119104842 $b ABA008
- 999 __
- $a ok $b bmc $g 1584292 $s 1106033
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 19 $c 1 $d 964 $e 20191017 $i 1471-2407 $m BMC cancer $n BMC Cancer $x MED00008171
- LZP __
- $a Pubmed-20201012
